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Acute kidney injury (AKI) can be fatal and is a well-defined risk factor for the development
of chronic kidney disease. Group 2 innate lymphoid cells (ILC2s) are innate producers of
type-2 cytokines and are critical regulators of homeostasis in peripheral organs. However,
our knowledge of their function in the kidney is relatively limited. Recent evidence
suggests that increasing ILC2 numbers by systemic administration of recombinant
interleukin (IL)-25 or IL-33 protects against renal injury. Whilst ILC2s can be induced
to protect against ischemic- or chemical-induced AKI, the impact of ILC2 deficiency or
depletion on the severity of renal injury is unknown. Firstly, the phenotype and location
of ILC2s in the kidney was assessed under homeostatic conditions. Kidney ILC2s
constitutively expressed high levels of IL-5 and were located in close proximity to the
renal vasculature. To test the functional role of ILC2s in the kidney, an experimental model
of renal ischemia-reperfusion injury (IRI) was used and the severity of injury was assessed
in wild-type, ILC2-reduced, ILC2-deficient, and ILC2-depleted mice. Surprisingly, there
were no differences in histopathology, collagen deposition or mRNA expression of
injury-associated (Lcn2), inflammatory (Cxcl1, Cxcl2, and Tnf ) or extracellular matrix
(Col1a1, Fn1) factors following IRI in the absence of ILC2s. These data suggest
the absence of ILC2s does not alter the severity of renal injury, suggesting possible
redundancy. Therefore, other mechanisms of type 2-mediated immune cell activation
likely compensate in the absence of ILC2s. Hence, a loss of ILC2s is unlikely to increase
susceptibility to, or severity of AKI.
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INTRODUCTION
Acute kidney injury (AKI) and its associated pathologies have profound effects on human health
(1). A common cause of AKI is renal ischemia, which primarily affects the tubular epithelium
due to the high mitochondrial density and metabolic activity in these cells (2); reviewed in
Devarajan (3) and Bonventre and Yang (4). Acute tubular necrosis impairs waste excretion, alters
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water and electrolyte imbalance, and causes robust inflammatory
responses; reviewed in Bonventre and Yang (4). Influx of
neutrophils and monocytes contributes to the injury, however
other innate immune cells can facilitate the return to homeostasis
(5); reviewed in Friedewald and Rabb (6). Innate lymphoid cells
(ILCs) are a recent addition to this family and are categorized into
3 groups based on the transcription factors that are required for
their development and by the effector cytokines they produce (7).
Group 2 ILCs (ILC2s) are potent producers of type 2 cytokines,
predominantly interleukin (IL)-5 and IL-13 (8, 9). These cells
also promote tissue recovery following insult in multiple organs
and have diverse functions in vivo (10). For example, following
respiratory viral infection with influenza virus, ILC2s co-
ordinate repair of the airway epithelium by producing the
growth factor amphiregulin (AREG) (11). More recently, ILC2s
have been investigated in models of renal injury including
ischemia-reperfusion injury (IRI), and nephrotoxic chemical-
induced injury with doxorubicin or cisplatin (12–16). Renal IRI
is typically achieved by temporarily restricting blood flow to
the kidney for 20–30min, modeling trauma from transplant or
surgical intervention (17–21). Collectively, these studies show
that in vivo administration of recombinant mouse cytokines that
activate ILC2s, namely IL-25 or IL-33, is sufficient to reduce
the severity of tubular epithelial cell injury (12–16). Similar
results have been achieved with adoptive transfer of ex vivo
activated ILC2s (12, 15). Whilst ILC2s can be artificially induced
to proliferate and protect against the deleterious consequences of
experimental renal injury, the impact of ILC2-deficiency remains
incompletely understood. Indeed, other immune cells, which
have complex interactions with the ILC2s such as regulatory
T cells (Treg) and alternatively activated macrophages (AAM;
also known as M2) are critical for this renoprotective effect
(22–25). In this study, we sought to further characterize ILC2s
in the kidney, their location within this organ and determine
their functional role in IRI using a loss-of-function approach.
Here, we found that kidney ILC2s constitutively express IL-
5 and are primarily located in close proximity to the renal
vasculature, within the adventitia. Additionally, we demonstrate
that a reduction, deficiency or depletion of ILC2s had minimal
impact on the severity of IRI. Whilst activation of ILC2s and
the associated amplification of local type 2 immunity has been
previously shown to reduce the deleterious consequences of
AKI, our results reveal that comparable injury occurs in the
absence of ILC2s, suggesting that ILC2s may be redundant in
IRI when other compensatory immune cells such as T cells
are present.
MATERIALS AND METHODS
Mice
Eight to twelve week-old male wild-type (WT; C57BL/6JAusb),
vehicle (saline-treated Icosdtr/+Cd4cre/+), ILC2-reduced
(Rorafl/+Il7rcre/+), ILC2-deficient (Rorafl/flIl7rcre/+), ILC2-
depleted (Diptheria toxoid-treated [DTx] Icosdtr/+ Cd4cre/+),
and IL-5/IL-13 dual reporter mice (Il5venus/+Il13td−tomato/+)
mice were obtained from Australian Bioresources (Moss Vale,
Australia). Il5td−tomatoCre; Rosa26-CAG-RFP reporter-tracker
mice were obtained from Jackson Labs (ref# 030926 and 007914).
All mice that underwent surgery were housed under specific
pathogen free, physical containment 2 conditions, in individually
ventilated cages. Mice were exposed to normal room air within
a sterilized environment during surgery. Mice were allowed 1
week to acclimatize before experiments were started and were
maintained on a 12-h day/night cycle with access to standard
laboratory chow and water ad libitum.
Flow Cytometry and t-SNE Analysis
Kidneys and lungs were collected from reporter mice. Single-cell
suspensions were prepared as described in “Preparation of
single-cell suspensions from mouse lung with Collagenase D
treatment” (Miltenyi Biotec GmbH, 2008; Bergisch Gladbach,
Germany). Cells were blocked with Fc block (purified anti-
mouse CD16/32; Biolegend, San Diego, USA) for 30min and
stained with fluorescently-conjugated antibodies against target
cell surface antigens (Supplementary Table 1). Staining and
washing steps were performed with BSA stain buffer (BD
Biosciences, North Ryde, Australia). Samples were acquired on
a BD LSR Fortessa X20 flow cytometer. Flow cytometry data
were analyzed using FlowJo v10.5.3 (Tree Star, Ashland, USA).
The t-distributed stochastic neighbor embedding (t-SNE) was
performed on ILC2s (CD45+Lineage−[TCR−[TCRαβ−TCRγδ−
CD8−CD4−]CD11b−GR-1−B220−TER-119−CD3−NK-1.1−]
IL7Rα+CD90.2+ST2+ FSClowSSClow single cells). Using the
random down sampling plugin, the number of events in each
sample was normalized to equal the lowest, rounded down
to the nearest 10 events. All populations were combined into
one .fcs file by concatenating the down sampled populations.
The t-SNE analysis was performed on the concatenated sample
containing the gated populations from all kidney and lung
samples combined. For this, the compensated channels that were
not used for gating were assessed under the following t-SNE
settings: Iteration 1000, Perplexity 20, Eta 224. Histograms were
used to show the differential expression of cell surface antigens
and cytokines in the lung and kidney.
Immunofluorescence
Il5td−tomatoCre; Rosa26-CAG-RFP reporter-tracker mice were
euthanized and perfused intracardially with phosphate buffered
saline (PBS) and then 4% paraformaldehyde (PFA) in PBS.
Kidneys were removed and kept in fresh 4% PFA for 24 h
at 4◦C and then washed in PBS. Three hundred micrometer
sections were prepared using a vibratome. Subsequently, tissue
sections were incubated in permeabilization buffer (PBS/0.2%
Triton X-100/0.3M glycine) then blocked in PBS/0.2% Triton X-
100/5% donkey serum at 4◦C overnight. Samples were washed
in PBS/0.2% Tween-20 once, then incubated with primary
antibodies diluted in PBS/0.2% Tween-20/3% donkey serum at
room temperature until the next day. Next, samples were washed
in PBS/0.2% Tween-20 for 30min, 3–4 times, then incubated
with secondary antibodies diluted in PBS/0.2% Tween-20/3%
donkey serum at room temperature for 6–8 h. Samples were
washed in PBS/0.2% Tween-20 for 1 day and then dehydrated
in an ascending ethanol series (20, 30, 50, 70, 95, 100%), 10min
each step. Finally, kidney sections were cleared by soaking in
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methyl salicylate (M-2047; Sigma-Aldrich, Castle Hill, Australia)
and then mounted in fresh methyl salicylate onto a concave
coverslip or chamber. Images were captured with Nikon A1R
laser scanning confocal including 405, 488, 561, and 650 laser
lines for excitation and imaging with 16X/0.8 or 25X1.1, NA
Plan Apo long working distance water immersion objectives.
Z steps were acquired every 6µm. Images were processed
with ImageJ (NIH, Bethesda, MD, US) and Bitplane Imaris
software v8 (Andor Technology PLC, Belfast, N. Ireland). Surface
reconstructions of alpha smooth muscle actin-labeled blood
vessels were performed with Imaris and pseudocolored based
on their characteristic architecture and volume to visualize large
arteries and veins. The following antibodies and dilutions were
used: Living Colors anti-DsRed Rabbit Polyclonal Pan Antibody
(1:500; TaKaRa, Mountain View, USA), goat polyclonal anti-
alpha smooth muscle actin antibody (1:200; Abcam, Cambridge,
UK), eFluor 660 LYVE1 monoclonal Antibody (1:300, clone
ALY7, eBioscience), armenian hamster anti-mouse CD3 antibody
(1:100, clone 145-2C11, Biolegend), Alexa Fluor R© 488 donkey
anti-goat IgG (H+L), Alexa Fluor R© 555 donkey anti-rabbit IgG
(H+L) Alexa Fluor R© 647 goat anti-hamster IgG (H+L) cross-
adsorbed (1:400, ThermoFisher Scientific).
Unilateral Ischemia-Reperfusion Injury
Surgical anesthesia was induced by 4% isoflurane inhalation
and maintained with continuous 1–1.5% isoflurane inhalation
through a nose cone. Throughout the procedure, mice were kept
on a surgical platform maintained at 37 ± 1◦C by a digital
thermostat-controlled heatmat. Nephrectomy of the right kidney
was performed in all animals. To induce unilateral ischemia the
vessels of the left kidney were clamped near the renal pedicle for
29-min using a non-traumatic sterile vascular clamp (Coherent
Scientific; Hilton, Australia) applying sufficient force to prevent
blood flow to and from the kidney without irreversible damage
to the vessels. Uniform and rapid reperfusion of the kidney was
observed after removing the vascular clamp in all mice. The
muscle and skin wounds were closed using a 5/0 vicryl suture
(Johnson & Johnson Medical, North Ryde, Australia), the skin
was then sealed using dermal adhesive (Provet, Charlestown,
Australia) to protect the wound and prevent infection. Control
animals were subjected to a sham operation with identical
anesthesia time and received only a contralateral nephrectomy.
For effective analgesia mice received 0.1 mg/kg of buprenorphine
subcutaneously 30min prior to the operation and then 0.05–0.1
mg/kg every 8–12 h, as required. Animals were typically weaned
off analgesia by 4 days post-surgery without any signs of pain
or distress as defined by facial characteristics using the standard
mouse grimace scale; as described (26). All mice survived to the
pre-determined endpoint.
Depletion of ILC2s in vivo
ILC2s were depleted in Icosdtr/+Cd4cre/+ mice by intraperitoneal
injection of 0.025 mg/kg of DTx (Sigma-Aldrich) as previously
described (27). DTx was administered 30min prior to surgery
and daily thereafter until the endpoint. To confirm ILC2-
depletion, a subset of naïve animals received DTx for 3
days. Control Icosdtr/+Cd4cre/+ mice received intraperitoneal
saline injection.
Histology
Excised kidneys were immediately sectioned in half
longitudinally through the hilum. Half was fixed in 10%
buffered formalin, containing 4% formaldehyde for 24 h before
temporary storage in 10% ethanol, paraffin embedding, and
sectioning. Four micrometer, longitudinally cut sections were
stained with periodic acid-Schiff (PAS) and Masson’s trichrome.
Histopathology was quantified by visualizing dilation of tubules,
apoptosis or cast formation by a single blinded investigator using
a well-established semi-quantitative method (28), with minor
alterations as described (15). An average was taken of the score
from duplicate PAS stained sections from each animal. A score
of 0= 0% of tubules were affected by the above histopathological
features; 1 = 1–10%; 2 = 11–25%; 3 = 26–50%; 4 = 51–75%; 5
= 76–100%. Collagen deposition was assessed using Masson’s
trichrome and collagen was identified as methyl blue content
between adjacent tubules.
RNA Extraction, Reverse Transcription,
and qPCR
Half of one kidney was retained for gene expression analysis.
The tissue was homogenized in 400 µl of PBS using a
TissueLyser LTTM (Qiagen, Chadstone Centre, Australia) through
50 oscillations per second for 2min. Two hundred microliter
of the sample was removed for other analyses. One milliliter
of TRI Reagent R© (Sigma-Aldrich) was added to the remaining
200 µl of the sample, which received a further 50 oscillations
per second for 1–2min until completely homogenized. Following
5min of incubation at room temperature and centrifugation
at 12,000x g for 10min, the supernatant was extracted and
vortexed with 250 µl of chloroform (Sigma-Aldrich). After
incubating for 10min at room temperature and centrifugation
at 12,000x g for 15min, the supernatant was extracted and
vortexed with 500 µl of 70% isopropanol (Sigma-Aldrich). The
sample was incubated again for 10min at room temperature
then was centrifuged at 12,000x g for 10min. The supernatant
was discarded without disrupting the RNA-rich pellet. The
pellet was washed twice with 1ml of 75% RNA-grade ethanol
(Sigma-Aldrich), centrifuged at 10,000x g for 5min and the
supernatant was discarded each time. The pellet was air-dried at
room-temperature briefly before re-suspending in 80–100 µl of
UltraPureTM DNase/RNase-free double distilled water (ddH2O;
Thermo-Fisher Scientific) and was then stored at −80◦C
prior to reverse transcription. Immediately prior to reverse
transcription, RNA yield was determined by spectrophotometric
assessment using a Nanodrop2000TM (Thermo-Fisher Scientific).
Five microliter of each sample was diluted in ddH2O such that
1,000 ng of RNA was loaded per sample. Following DNAse
(Sigma-Aldrich) treatment, cDNA was generated using the M-
MLV (Thermo-Fisher Scientific, North Ryde, Australia) enzyme
standard operating procedures using a T100TM thermal cycler
(BioRad Laboratories, Gladesville, Australia). Using SYBR based
methodology, qPCR was performed using CFX384 TouchTM
(BioRad Laboratories) as per standard operating procedures.
Each primer set was gradient tested to determine the optimal
temperature for amplification (Supplementary Table 2). Cycle
quantification was interpreted using regression for each target,
gene expression was normalized relative to hypoxanthine
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guanine phosphoribosyl transferase (Hprt). Melt curves were
assessed for signs of primer dimerization and non-specific
amplification. On every plate, at least one negative control
and no-template control was used for each target to ensure
contamination was not present within each master mix or the
ddH2O used.
RT2 Profiler Array
RT² ProfilerTM PCR Array Mouse Extracellular Matrix
& Adhesion Molecules (Qiagen) was performed as per
manufacturer’s instructions and data was uploaded then
analyzed by the online tool, available from: https://dataanalysis.
qiagen.com/pcr/arrayanalysis.php. This array allows profiling of
84 genes in a maximum of 4 samples, therefore, equal amounts
of cDNA for each replicate in a group were pooled from WT
mice on day 1, 3, or 7 following IRI, and sham pooled from each
replicate from each of these timepoints. For each target, the fold
change following IRI was compared to sham expression.
Statistical Analysis
All data were analyzed with Graphpad Prism software v8.02
using non-parametric unpaired t-tests (Mann-Whitney U-test).
P < 0.05 was set as threshold for determining statistically
significant differences. ∗P < 0.05, ns not significant. All data are
expressed as mean ± SEM. In each analysis there were n = 4–8
replicates per group and results were representative of at least two
experiments. Sample size for each experiment is described in the
corresponding figure legend.
RESULTS
Renal ILC2s Constitutively Express IL-5
and Are Localized to the Renal Vasculature
Under Homeostatic Conditions
A detailed analysis of renal ILC2 phenotype and location
under homeostatic conditions was performed. There
were significantly more ILC2s (CD45+Lineage−IL-
7Rα+CD90.2+ST2+FSClowSSClow single cells), in the kidney
compared to the lung when represented as a percentage of total
CD45+ single cells (Figure 1A; Supplementary Figures 1A, B).
t-SNE analysis of kidney and lung ILC2s showed unique
clustering, although these clusters were not entirely distinct from
one another (Figure 1B). However, kidney ILC2s had markedly
lower expression of CD25, consistent expression of ICOS and
KLRG1, but higher expression of IL-5 compared to lung ILC2s
(Figure 1C). Kidney ILC2s had higher constitutive expression
of IL-5 than IL-13 (Figure 1D; Supplementary Figures 1C, D).
ILC2s were determined to be the major IL-5 producing cell
type in the kidney, with a negligible contribution from T helper
type-2 (TH2) cells (Figure 1E, Supplementary Figures 1E, F).
Therefore, IL-5 was used as a surrogate marker to identify the
location of ILC2s within the mouse kidney, as has been described
for multiple peripheral organs (29–31). This was achieved by
utilizing mice that express an IL-5 linked cre-recombinase
crossed to a Rosa-tdtomato lineage tracker (30, 31). IL-5+ cells
(predominantly ILC2s) were found throughout the kidney, but
were primarily localized to the major vasculature, as visualized
FIGURE 1 | ILC2s are present in the kidney and have a unique signature
compared to lung ILC2s. (A) ILC2s (CD45+Lineage− [TCR−[TCRαβ−
TCRγδ−CD8−CD4−]CD11b−GR-1−B220−TER-119−CD3−NK-1.1−]IL-
7Rα+CD90.2+ST2+FSClowSSClow single cells) in kidney and lung single cell
suspensions from naïve Il5venus/+ Il13td−tomato/+ mice, n = 8. (B)
Comparison of lung and kidney ILC2s by t-distributed stochastic neighbor
embedding (t-SNE) analysis based on the cell surface antigens CD25, ICOS,
KLRG1, and the type 2 effector cytokines IL-5 and IL-13. (C) Differential
expression of ILC2-associated cell surface antigens and type 2 effector
cytokines. (D) Percentage of IL-5+ and IL-13+ renal ILC2s. (E) Proportions of
CD45+CD19−CD11b−CD49b−CD90.2+ IL-5+ single cells which were
consistent with ILC2s (CD3−CD4−) and TH2s (CD3
+CD4+) in kidney single
cell suspensions from Il5td−tomatoCre; Rosa-CAG-RFP mice, n = 8. All data
are expressed as mean ±SEM. *P < 0.05 by Mann-Whitney U-test.
with alpha smooth muscle actin (α-SMA) positive staining
(Figure 2A; Supplementary Figures 2A, B), consistent with
our recent report (29). ILC2s were found to be associated
with both interlobular and arcuate renal vessels in the cortex
and medullary regions, as shown by lymphatic endothelial
hyaluronan receptor-1 (LYVE1) expression (Figure 2B).
Further imaging demonstrated that very few of the CD3+ cells
(predominantly TH2 cells) contributed to the endogenous IL-5
+
signal (Figure 2C). ILC2s were identified in the adventitia of
the vessel using pseudocolored surface reconstructions of the
arterial α-SMA.
Reduction, Deficiency, or Depletion of
ILC2s Does Not Alter the Severity of
Experimental Renal Ischemia-Reperfusion
Injury in Mice
Given ILC2s were present in the kidney and localized to the
renal vasculature, the impact of ILC2 reduction, deficiency or
depletion on the severity of experimental renal IRI was assessed.
This was achieved by using ILC2-reduced (Rorafl/+Il7rcre/+),
Frontiers in Immunology | www.frontiersin.org 4 April 2019 | Volume 10 | Article 826
Cameron et al. ILC2 Redundancy in Kidney Injury
FIGURE 2 | Kidney ILC2s are localized around the vasculature under homeostatic conditions. Kidney sections from Il5td−tomatoCre; Rosa-CAG-RFP mice were
stained for IL-5+ cells (predominantly ILC2s), the IL-5+ pixel surface area was increased to improve clarity, tissue sections were co-stained for α-SMA for structure
determination. (A) Gross structure of the kidney, ILC2s were located in close proximity to the renal vessels throughout the tissue. (B) A magnified view of a vessel
(Continued)
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FIGURE 2 | spanning regions of the kidney with the addition of DAPI; LYVE1 staining indicates lymphatics which track vasculature in the cortex, ILC2s displayed no
preference toward medullary or cortical vessels. (C) CD3+ cells (predominantly TH2 cells) contributed negligible IL-5
+ signal. Background and arterial α-SMA staining
demonstrates ILC2s and TH2 cells are located in the adventitia of the vessel. Blue arrows indicate IL-5 and CD3 co-localization in the same cell, yellow arrows indicate
partial co-localization from adjacent cells.
-deficient (Rorafl/flIl7rcre/+), and -depleted (DTx-treated
Icosdtr/+Cd4cre/+) mice compared to WT and vehicle (saline-
treated Icosdtr/+Cd4cre/+) controls. These mice have been
previously described as appropriate tools for assessing ILC2
function in vivo in other organs such as the lung (27, 32). Here
we show that these tools are also appropriate for assessing ILC2
function in the kidney. Indeed, kidney ILC2s were significantly
lower in the ILC2-reduced, -deficient, and -depleted groups
compared to WT or saline-treated controls (Figure 3A). Time
course analysis of IRI in wild-type mice identified day 7 as
the most appropriate time point for the assessment of injury
severity due to the presence of histopathological features of
acute tubular necrosis, collagen deposition and increased
mRNA expression of extracellular matrix, injury-associated,
and inflammatory factors (Supplementary Figures 3, 4). At day
7, 25/84 extracellular matrix factors were increased >2-fold
compared to sham controls, whilst 1/84 and 6/84 were increased
at day 1 and 3, respectively (Supplementary Figure 4A). IRI
induced acute tubular necrosis characterized by dilated tubules
and cast formation, compared to sham controls (Figure 3B,
Supplementary Figures 3A, 4B). This was quantified as a
tubular injury score and the severity of injury was similar in all
genotypes (Figure 3C). IRI also induced collagen deposition,
marked by methyl blue content between the tubules in the
medulla and cortex, compared to sham controls (Figure 3D;
Supplementary Figure 3B). Collagen deposition was unaffected
by the absence of ILC2s. IRI also increased the mRNA expression
of injury-associated factors, chemokines, and pro-inflammatory
cytokines (Figures 3E–J, Supplementary Figures 4C–K).
Neutrophil gelatinase-associated lipocalin, (Lcn2; NGAL),
a biomarker of renal injury (33, 34), was increased by IRI
and unaffected by ILC2 reduction, deficiency, or depletion
(Figure 3E). C-X-C motif chemokine ligand 1 (Cxcl1) and
Cxcl2 were also significantly increased by IRI in all genotypes
(Figures 3F,G). Similarly, the pro-inflammatory cytokine
tumor necrosis factor (Tnf ) was increased by IRI, compared
to sham controls (Figure 3H). Consistent with visible collagen
deposition, mRNA expression of the extracellular matrix factors
collagen type I alpha 1 chain (Col1a1), and fibronectin 1 (Fn1)
were increased by IRI in all genotypes (Figures 3I,J).
DISCUSSION
ILC2s are critical regulators of tissue homeostasis, but their role
in the kidney remains to be fully elucidated. Whilst ILC2s can
be induced to proliferate and protect against the deleterious
consequences of experimental renal injury, it is not yet known
what occurs in the absence of these cells. We first examined
whether ILC2 numbers, as a proportion of CD45+ hematopoietic
cells, are different in lung and kidney. ILC2s accounted for a
greater proportion of CD45+ cells in the kidney than in the
lung. t-SNE analysis grouped ILC2s from both sites differently,
however the clusters were not entirely distinct between these
tissues. There were differences in their cell surface antigen and
type 2 cytokine expression, with kidney ILC2s expressing greater
amounts of IL-5. Indeed, kidney ILC2s constitutively expressed
high levels of IL-5 under homeostatic conditions. ILC2s were
also the major source of IL-5 in the kidney, with negligible
contribution from TH2 cells. Therefore, IL-5 was used as a
surrogate marker to determine the location of these cells in
the kidney. ILC2s were identified within the kidney and were
localized almost exclusively along the renal vasculature. In these
studies, an IL-5 linked cre-recombinase was used in conjunction
with a flox-stop-flox sequence upstream of a CAG-RFP-WPRE-
cassette in the constitutively expressed ROSA26 locus to locate
the ILC2s. LYVE1, which is expressed by renal lymphatic
endothelial cells, was used to further define the location of these
cells within the mouse kidney (35). As expected, LYVE1 staining
was embedded within the connective tissue of renal arteries of the
cortex, but not within themedulla since no discernable lymphatic
network exists in this region of the kidney (35–37). Presumably
ILC2s are situated close to the vascular as renal endothelial cells
are a major source of IL-33 in the kidney (38, 39). Confirming
our observation by FACS of single cell kidney suspensions, ILC2s
were again found to be the major producers of IL-5 in kidney
tissue sections, with minimal contribution from CD3+ T cells.
Whilst these studies show the location of ILC2s in the kidney
using reporter mice, it remains to be determined if ILC2s are
also located adjacent to the vasculature in the human kidney,
and whether the location of ILC2s is altered in response to renal
injury. Although multiple reports have found ILC2 numbers are
unchanged by renal injury, their phenotype and activation state
following injury requires further elucidation (12–16). Next, we
characterized the functional role of ILC2s in the kidney using a
loss-of-function approach. To achieve this, we took advantage
of ILC2-reduced and -deficient mice, and mice that can be
conditionally depleted of ILC2s following the administration of
DTx (27). We validated the use of these tools for knockdown
or ablation of ILC2s in the kidney. An experimental model
of IRI was chosen, given the proximity of ILC2s to the renal
vasculature. Although features of injury were visibly evident
following IRI, a reduction, deficiency, or depletion in ILC2s
did not alter gross histopathology in the kidney, nor did it
cause mortality. Indeed, IRI-induced remodeling and collagen
deposition occurred independent of ILC2s. Whilst it is possible
that an earlier time point following injury may have identified
differences in histopathology and gene expression, the time point
in our study also allowed assessment of collagen deposition, an
important feature of remodeling that is regulated by ILC2s (16,
32, 40–44). It is also plausible that a reduction in ILC2s during
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FIGURE 3 | A reduction, absence or depletion of ILC2s does not alter the severity of experimental renal ischemia-reperfusion injury. All mice were subjected to 29-min
unilateral IRI with contralateral nephrectomy and were assessed compared to sham surgical controls for each genotype. All parameters were assessed 7 days after
injury. (A) Kidney ILC2s (CD45+Lineage−[TCR−[TCRαβ−TCRγδ−CD8−CD4−]CD11b−GR-1−B220−TER-119−CD3−NK-1.1−]IL-7Rα+
CD90.2+ST2+FSClowSSClow single cells) as a percentage of CD45+ single cells from naïve C57BL/6JAusB wild-type (WT, n = 6; uncolored), vehicle (saline-treated
Icosdtr/+Cd4cre/+, n = 8; teal), ILC2-reduced (Rorafl/+ Il7rcre/+, n = 7; blue), ILC2-deficient (Rorafl/fl Il7rcre/+, n = 5; red), and ILC2-depleted
(DTx-treated-Icosdtr/+Cd4cre/+, n = 8; purple) mice. (B) Representative images of periodic acid-Schiff stained kidney sections from control (WT, n = 8; Saline, n = 5)
and ↓ILC2 (ILC2-reduced, n = 4; -deficient, n = 4 & -depleted, n = 5) showing dilated tubules and cast formation. (C) Semi-quantitative tubular injury score indicating
injury in terms of the proportion of tubules effected by casts, dilation, apoptosis, and/or loss of brush border, where a score of 5 indicates 76-100% of tubules were
affected. (D) Representative images of Masson’s trichrome stained kidney sections following IRI, blue staining indicates collagen deposition. (E–J) mRNA expression
of injury (Lcn2), inflammatory (Cxcl1, Cxcl2, and Tnf ), and extracellular matrix (Col1a1 and Fn1) factors in kidney homogenates relative to Hprt. Scale bar in each
image indicates 100µm. All data are expressed as mean ± SEM. *P < 0.05, ns not significant; by Mann-Whitney U-test.
AKI could be detrimental to kidney structure and function, when
assessed at later time points due to potential maladaptive repair
responses in the absence of ILC2s. To address this, future studies
will need to investigate the role of ILC2s in the progression of
AKI to chronic kidney disease (45, 46).
Collectively, this study demonstrates that a reduction,
deficiency or depletion in ILC2s does not alter the severity
of experimental AKI in mice. Whilst activation of ILC2s and
the associated amplification of local type 2 immunity has been
previously shown to reduce the deleterious consequences of AKI,
comparable injury occurs when ILC2s are reduced, absent or
depleted suggesting possible redundancy and compensation by
other immune cells, such as Treg, AAM, and TH2 cells. This
concept is supported by studies using Rag1−/− or Rag2−/−
mice that lack mature T and B cells, in models of kidney
injury (13, 15, 47, 48). In one study, anti-CD90.2 administration
was used to deplete ILC2s, however these animals were also
deficient in Treg and TH2 cells (15). In this model system,
despite the depletion of ILC2s with anti-CD90.2, compensation
from the T cell compartment is not possible. Our data show
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that a loss of ILC2s, when the T cell compartment remains
intact, has minimal effects on the severity of IRI. Our data
supports the concept that the ILC2s in addition to other immune
cells, such as Treg and AAM, contribute to AKI. Indeed, Treg
depletion worsened histopathology following IRI (15). Similarly,
macrophage polarization toward AAM promotes the resolution
of injury (5, 12, 46, 49, 50). Further studies are required to
elucidate the reason for the presence of ILC2s in the kidney,
including ascending urinary tract infections and other renal
insults as well as in progression to chronic disease.
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